Your browser doesn't support javascript.
loading
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
De Jonge, A Vera; Bruins, Wassilis S C; Duetz, Carolien; Korst, Charlotte L B M; Rentenaar, Rosa; Cosovic, Meliha; Eken, Merve; Kersten, Marie-Jose; Sandberg, Yorick; Van Rijn, Rozemarijn S; Fijnheer, Rob; Mutsaers, Pim; Vergote, Vibeke K J; Issa, Djamila; Beeker, Aart; Bilgin, Yavuz M; Visser, Otto; Van Werkhoven, Erik; Roemer, Margaretha G M; Chamuleau, Martine E D; Mutis, Tuna.
Affiliation
  • De Jonge AV; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Bruins WSC; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Duetz C; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Korst CLBM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Rentenaar R; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Cosovic M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Eken M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Kersten MJ; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Sandberg Y; Department of Internal Medicine, Maasstad Hospital, Rotterdam.
  • Van Rijn RS; Department of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden.
  • Fijnheer R; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort.
  • Mutsaers P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam.
  • Vergote VKJ; Department of Hematology, University Hospitals Leuven, Leuven.
  • Issa D; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch.
  • Beeker A; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp.
  • Bilgin YM; Department of Internal Medicine, Adrz, Goes.
  • Visser O; Department of Internal medicine, Isala, Zwolle.
  • Van Werkhoven E; HOVON foundation, Rotterdam, The Netherlands; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam.
  • Roemer MGM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Chamuleau MED; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.
  • Mutis T; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam. t.mutis@amsterdamumc.nl.
Haematologica ; 2024 Jul 04.
Article in En | MEDLINE | ID: mdl-38961740
ABSTRACT
Not available.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2024 Type: Article